Promega

Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.

The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.

Novacyt said this week that its revenue from continuing operations for full-year 2018 will be in the range of €13.7 million to €14.4 million ($17.4 million to $18.3 million), following its decision in December to sell its Novaprep cytology business and clinical laboratory operations.

The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.